Splice variant insertions in the C-terminus impairs YAP's transactivation domain

Biochemistry and Biophysics Reports

Volumn 6, Issue , 2016, Pages 24-31

  Finch Edmondson, Megan L ^a   Strauss, Robyn P ^a,b   Clayton, Joshua S ^a   Yeoh, George C ^a,b   Callus, Bernard A ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF NOTRE DAME   (Australia)

Author keywords

Alternate splicing; Luciferase assay; Transcriptional co activator; Yes associated protein (YAP)

Indexed keywords

LEUCINE ZIPPER PROTEIN; LUCIFERASE; TRANSCRIPTION FACTOR GAL4; TRANSCRIPTION FACTOR YAP1; TRANSCRIPTION FACTOR YAP1 ALPHA 1; TRANSCRIPTION FACTOR YAP1 ALPHA 2; TRANSCRIPTION FACTOR YAP1 BETA 1; TRANSCRIPTION FACTOR YAP1 GAMMA 2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME ACTIVITY; GAL4 GENE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PDZ DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN STABILITY; TRANSACTIVATION; TRANSCRIPTION INITIATION;

EID: 84960360197     PISSN: None     EISSN: 24055808     Source Type: Journal    
DOI: 10.1016/j.bbrep.2016.02.015     Document Type: Article

References (37)

1. Yagi R., Chen L.F., Shigesada K., et al. A WW domain-containing yes-associated protein (YAP) is a novel Transcriptional co-activator. EMBO J. 1999, 18:2551-2562.
2. Dong J., Feldmann G., Huang J., et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007, 130:1120-1133.
3. Hao Y.W., Chun A., Cheung K., et al. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J. Biol. Chem. 2008, 283:5496-5509.
4. Huang J.B., Wu S., Barrera J., et al. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell 2005, 122:421-434.
5. Zhang J., Smolen G.A., Haber D.A. Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. Cancer Res. 2008, 68:2789-2794.
6. Cao X., Pfaff S.L., Gage F.H. YAP regulates neural progenitor cell number via the TEA domain transcription factor. Genes Dev. 2008, 22:3320-3334.
7. Zhao B., Ye X., Yu J., et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008, 22:1-10.
8. Zhang J., Ji J.Y., Yu M., et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat. Cell Biol. 2009, 11:1444-1450.
9. Sudol M., Shields D.C., Farooq A. Structures of YAP protein domains reveal promising targets for development of new cancer drugs. Semin. Cell Dev. Biol. 2012, 23:827-833.
10. Gaffney C.J., Oka T., Mazack V., et al. Identification, basic characterization and evolutionary analysis of differentially spliced mRNA isoforms of human YAP1 gene. Gene 2012, 509:215-222.
11. Chen L., Chan S.W., Zhang X., et al. Structural basis of YAP recognition by TEAD4 in the Hippo pathway. Genes Dev. 2010, 24:290-300.
12. Li Z., Zhao B., Wang P., et al. Structural insights into the YAP and TEAD complex. Genes Dev. 2010, 24:235-240.
13. Strano S., Munarriz E., Rossi M., et al. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J. Biol. Chem. 2001, 276:15164-15173.
14. Komuro A., Nagai M., Navin N.E., et al. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J. Biol. Chem. 2003, 278:33334-33341.
15. Oka T., Remue E., Meerschaert K., et al. Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. Biochem. J. 2010, 432:461-472.
16. Oka T., Sudol M. Nuclear localization and pro-apoptotic signaling of YAP2 require intact PDZ-binding motif. Genes Cells 2009, 14:607-615.
17. Landschulz W.H., Johnson P.F., McKnight S.L. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science 1988, 240:1759-1764.
18. Sudol M. YAP1 oncogene and its eight isoforms. Oncogene 2013, 32. 3922-3922.
19. Liu X., Yang N., Figel S.A., et al. PTPN14 interacts with and negatively regulates the oncogenic function of YAP. Oncogene 2013, 32:1266-1273.
20. Overholtzer M., Zhang J., Smolen G.A., et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc. Natl. Acad. Sci. USA 2006, 103:12405-12410.
21. Ehsanian R., Brown M., Lu H., et al. YAP dysregulation by phosphorylation or δNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets. Oncogene 2010, 29:6160-6171.
22. Oka T., Mazack V., Sudol M. Mst2 and Lats kinases regulate apoptotic function of yes kinase-associated protein (YAP). J. Biol. Chem. 2008, 283:27534-27546.
23. Zhang X., Milton C.C., Poon C.L.C., et al. Wbp2 cooperates with Yorkie to drive tissue growth downstream of the Salvador-Warts-Hippo pathway. Cell Death Differ. 2011, 18:1346-1355.
24. Zhao B., Kim J., Ye X., et al. Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of Yes-associated protein. Cancer Res. 2009, 69:1089-1098.
25. Zhang X., Milton C.C., Humbert P.O., et al. Transcriptional output of the Salvador/Warts/Hippo pathway is controlled in distinct fashions in Drosophila melanogaster and mammalian cell lines. Cancer Res. 2009, 69:6033-6041.
26. Zhang X., Grusche F.A., Harvey K.F. Control of tissue growth and cell transformation by the Salvador/Warts/Hippo pathway. PLoS One 2012, 7:e31994.
27. Xia Y., Chang T., Wang Y., et al. Yap promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients. PLoS One 2014, 9:e91770.
28. Zhang H., Deo M., Thompson R.C., et al. Negative regulation of Yap during neuronal differentiation. Dev. Biol. 2012, 361:103-115.
29. Vassilev A., Kaneko K.J., Shu H.J., et al. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev. 2001, 15:1229-1241.
30. Callus B.A., Mathey-Prevot B. Rapid selection of tetracycline-controlled inducible cell Lines using a green fluorescent-transactivator fusion protein. Biochem. Biophys. Res. Commun. 1999, 257:874-878.
31. Callus B.A., Mathey-Prevot B. Hydrophobic residues Phe751 and Leu753 are essential for Stat5 transcriptional activity. J. Biol. Chem. 2000, 275:16954-16962.
32. Callus B.A., Ekert P.G., Heraud J.E., et al. Cytoplasmic p53 is not required for PUMA-induced apoptosis. Cell Death Differ. 2008, 15:213-215.
33. Dunning C.J.R., McKenzie M., Sugiana C., et al. Human CIA30 is involved in the early assembly of mitochondrial complex I and mutations in its gene cause disease. EMBO J. 2007, 26:3227-3237.
34. Finch M.L., Passman A.M., Strauss R.P., et al. Sub-cellular localisation studies may spuriously detect the Yes-associated protein, YAP, in nucleoli leading to potentially invalid conclusions of its function. PLoS One 2015, 10:e0114813.
35. McDonald C.B., McIntosh S.K.N., Mikles D.C., et al. Biophysical analysis of binding of WW domains of the YAP2 transcriptional regulator to PPXY motifs within WBP1 and WBP2 adaptors. Biochemistry 2011, 50:9616-9627.
36. Oka T., Schmitt A.P., Sudol M. Opposing roles of angiomotin-like-1 and Zona Occludens-2 on pro-apoptotic function of YAP. Oncogene 2012, 31:128-134.
37. Tsutsumi R., Masoudi M., Takahashi A., et al. YAP and TAZ, Hippo signaling targets, act as a rheostat for nuclear SHP2 function. Dev. Cell 2013, 26:658-665.